Loading...
XASXBOD
Market cap2mUSD
Nov 23, Last price  
0.02AUD
Name

Bod Science Ltd

Chart & Performance

D1W1MN
XASX:BOD chart
P/E
—
P/S
4.86
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.20%
Rev. gr., 5y
1.31%
Revenues
876k
-49.04%
115,6050352,877852,783820,2215,013,9976,578,4023,424,6431,718,190875,559
Net income
-6m
L-19.37%
-257,0750-3,168,615-3,672,105-7,623,571-4,819,140-4,226,105-5,406,544-7,953,136-6,412,941
CFO
-914k
L-83.90%
0-214,91400-6,483,144-3,223,447-5,833,027-4,176,355-5,677,740-913,978
Earnings
Mar 26, 2025

Profile

Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through three segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, and OTC Herbals. It engages in the development and manufacture of cannabidiol and hemp products for consumers; and development and distribution of therapeutics medicinal cannabis products for medical markets. The company provides Flexofytol, an anti-inflammatory derived from a scientifically validated and clinically trialed turmeric extract that helps in improving joint health, limiting the ageing of cartilage, and reducing inflammation caused by mild arthritis; and Sedistress, a passion flower extract that reduces the symptoms of stress, anxiety, and insomnia. The company was formerly known as Bod Australia Limited and changed its name to Bod Science Limited in December 2022. Bod Science Limited was incorporated in 2014 and is based in Double Bay, Australia.
URL
https://bodscience.com/
IPO date
Oct 27, 2016
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
876
-49.04%
1,718
-49.83%
3,425
-47.94%
Cost of revenue
4,160
12,687
9,178
Unusual Expense (Income)
NOPBT
(3,285)
(10,969)
(5,754)
NOPBT Margin
Operating Taxes
(1,981)
(1,357)
17
Tax Rate
NOPAT
(1,304)
(9,613)
(5,771)
Net income
(6,413)
-19.37%
(7,953)
47.10%
(5,407)
27.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,784
3,202
BB yield
-32.83%
Debt
Debt current
1,831
963
(11)
Long-term debt
Deferred revenue
Other long-term liabilities
49
589
63
Net debt
1,396
(1,068)
(3,677)
Cash flow
Cash from operating activities
(914)
(5,678)
(4,176)
CAPEX
(1,959)
(148)
(207)
Cash from investing activities
(1,938)
(290)
(207)
Cash from financing activities
765
4,138
FCF
2,232
(9,673)
(5,756)
Balance
Cash
434
2,031
3,666
Long term investments
Excess cash
391
1,945
3,495
Stockholders' equity
(5,318)
(703)
3,467
Invested Capital
1,880
1,545
52
ROIC
ROCE
95.52%
EV
Common stock shares outstanding
174,274
141,360
107,341
Price
0.07
-1.43%
0.07
-79.10%
Market cap
9,754
29.81%
7,514
-77.68%
EV
8,686
3,837
EBITDA
(3,076)
(10,797)
(5,600)
EV/EBITDA
Interest
152
27
Interest/NOPBT